Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity

被引:21
|
作者
Fournier, B
Hooper, DC
机构
[1] Harvard Univ, Div Infect Dis, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA
[2] Harvard Univ, Med Serv, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA
关键词
D O I
10.1128/AAC.42.8.2109
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The grlA genes of Staphylococcus aureus ISP794 (wild type), MT5224c4 (grlA [Phe-80]), MT5224c2 (grlA [Pro-116]), and MT111 (grlA [Glu-116]) were cloned in pSK950, a shuttle vector, and introduced into S, aureus strains derived from strain RN4220. The mutations at position 116 of GrlA (Ala-->Pro or Glu) caused an increase in the level of fluoroquinolone resistance and a decrease in the level of coumarin susceptibility, whereas the mutation at position 80 (Ser-->Phe) caused only an increase in the level of fluoroquinolone resistance. In multicopy alleles, both types of mutations were codominant for fluoroquinolone resistance, and mutations at position 116 were also codominant for coumarin resistance.
引用
收藏
页码:2109 / 2112
页数:4
相关论文
共 50 条
  • [1] Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus:: Novel pleiotropic effects an quinolone and coumarin activity
    Fournier, B
    Hooper, DC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) : 121 - 128
  • [2] Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus
    Yamagishi, JI
    Kojima, T
    Oyamada, Y
    Fujimoto, K
    Hattori, H
    Nakamura, S
    Inoue, M
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) : 1157 - 1163
  • [3] Analysis of grlA mutations in clinical isolates of Staphylococcus aureus with different levels of quinolone resistance
    Martínez, JA
    Ortiz, G
    Segovia, M
    Alonso, MA
    Gutiérrez, MN
    Muñoz, JL
    García-Rodríguez, JA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) : 1306 - 1307
  • [4] Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus
    Ng, EY
    Trucksis, M
    Hooper, DC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) : 1881 - 1888
  • [5] Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus
    Takahata, M
    Yonezawa, M
    Kurose, S
    Futakuchi, N
    Matsubara, N
    Watanabe, Y
    Narita, H
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (03) : 543 - 546
  • [6] Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains
    Wang, T
    Tanaka, M
    Sato, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (02) : 236 - 240
  • [7] Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model
    Oonishi, Yoshimi
    Mitsuyama, Junichi
    Yamaguchi, Keizo
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (05) : 1030 - 1037
  • [8] Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus
    Deplano, A
    Zekhnini, A
    Allali, N
    Couturier, M
    Struelens, MJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) : 2023 - 2025
  • [9] Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC
    Schmitz, FJ
    Jones, ME
    Hofmann, B
    Hansen, B
    Scheuring, S
    Lückefahr, M
    Fluit, A
    Verhoef, J
    Hadding, U
    Heinz, HP
    Köhrer, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) : 1249 - 1252
  • [10] Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus
    Tanaka, M
    Onodera, Y
    Uchida, Y
    Sato, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) : 3044 - 3046